Beximco Pharma. - Q3 Financial Results 2025-26
24 June 2026
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
BEXIMCO PHARMACEUTICALS PLC.
Q3 Financial Results 2025-26
Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.:213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients today announces its unaudited financial results for the third quarter and nine months ended 31 March 2026.
Financial Highlights (Consolidated)
Nine months ended 31 March 2026
· Net sales increased 13.1% to Bangladesh Taka ("BDT") 41,428.0m / £256.9m (2024-25: BDT 36,622.0m / £235.0m)
o Domestic sales increased 14.4% to BDT 38,459.2m / £238.5m (2024-25: BDT 33,617.7m / £215.7m)
o Export sales decreased 1.2% to BDT 2,968.8m / £18.4m (2024-25: BDT 3,004.3m / £19.3m)
· Profit after tax increased 34.0% to BDT 7,048.6m / £43.7m (2024-25: BDT 5,261.0m / £33.8m)
Third-quarter ended 31 March 2026
· Net sales increased 8.1% to BDT 13,627.8m / £84.5m (2024-25: BDT 12,608.6m / £80.9m)
· Profit after tax increased 30.6% to BDT 2,254.4m / £14.0m (2024-25: BDT 1,726.0m / £11.1m)
The detailed accounts can be viewed at the Company website: www.beximcopharma.com
For a summary of financial and operational highlights for the period from 1 January 2025 to 31 March 2026, please refer to the previous announcement titled: "Financial Results for the Periods from 1 January 2025 to 31 March 2026", released today.
(Exchange rates of £1=Taka 161.2895 for 31 March 2026 and £1=Taka 155.8649 for 31 March 2025 have been used in this announcement.)
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext. 20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext. 20030
Mohammad Asad Ullah, FCS
Executive Director & Company Secretary
Tel: +880 2 41060531, Ext. 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Sam Purewal / Lucy Molloy
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals PLC.
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.
Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of financial position (Un-audited)
As at March 31, 2026
March 31, 2026
Taka '000
June 30, 2025
ASSETS
Non-current assets
50,664,655
49,461,242
Property, plant and equipment
44,822,991
43,541,872
Right-of-use assets
423,012
485,613
Intangible assets
4,689,328
4,694,134
Deferred tax asset
33,780
44,079
Goodwill
674,570
674,570
Other investments
20,974
20,974
Current assets
28,066,596
23,786,005
Inventories
14,225,662
13,586,476
Spares and supplies
966,481
799,644
Trade and other receivables
3,768,406
3,628,788
Loans, advances, deposits and prepayments
3,528,252
2,814,492
Advance income tax
400,152
356,508
Short term investment
950,000
900,000
Cash and cash equivalents
4,227,643
1,700,097
TOTAL ASSETS
78,731,251
73,247,247
EQUITY AND LIABILITIES
Equity attributable to the owners of the company
60,048,483
53,107,137
Share capital
4,461,121
4,461,121
Share premium
5,269,475
5,269,475
Excess of issue price over face value of GDRs
1,689,637
1,689,637
Capital reserve on merger
294,951
294,951
Revaluation surplus
1,131,583
1,133,870
Unrealized gain/(loss)
18,149
18,149
Retained earnings
47,183,567
40,239,934
Non-controlling interest
4,047,682
3,977,499
TOTAL EQUITY
64,096,165
57,084,636
Non-current liabilities
7,831,707
7,769,471
Long term borrowings-net of current maturity
1,298,330
1,503,595
Liability for gratuity, pension and WPPF
3,951,697
3,690,096
Deferred tax liability
2,581,680
2,575,780
Current liabilities
6,803,379
8,393,140
Short term borrowings
973,567
2,025,394
Long term borrowings-current maturity
891,550
1,436,752
Trade and other payables
2,124,152
2,925,994
Accrued expenses
1,394,433
1,174,096
Dividend payable
137,932
302,272
Income tax payable
1,281,745
528,632
TOTAL LIABILITIES
14,635,086
16,162,611
TOTAL EQUITY AND LIABILITIES
78,731,251
73,247,247
Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of profit or loss and other comprehensive income (Un-audited)
For the period July 2025- March 2026
Taka '000
July 2025 -
March 2026
July 2024 -
March 2025
January - March 2026
January - March 2025
Net revenue
41,427,963
36,621,960
13,627,807
12,608,553
Cost of goods sold
(21,118,060)
(19,822,775)
(6,931,325)
(6,787,928)
Gross profit
20,309,903
16,799,185
6,696,482
5,820,625
Operating expenses
(10,737,944)
(9,288,133)
(3,687,910)
(3,397,216)
General and administrative expenses
(1,133,559)
(1,026,632)
(381,590)
(338,255)
Selling, marketing and distribution expenses
(9,604,385)
(8,261,501)
(3,306,320)
(3,058,961)
Profit from operations
9,571,959
7,511,052
3,008,572
2,423,409
Other income
566,312
481,900
193,267
255,344
Finance cost
(519,609)
(802,608)
(146,061)
(314,630)
Profit before tax and WPPF
9,618,662
7,190,344
3,055,778
2,364,123
Contribution to WPPF
(467,208)
(351,606)
(148,998)
(116,347)
Profit before tax
9,151,454
6,838,738
2,906,780
2,247,776
Income tax expenses
(2,102,822)
(1,577,731)
(652,351)
(521,780)
Current tax
(2,085,959)
(1,580,974)
(651,677)
(517,572)
Deferred tax
(16,863)
3,243
(674)
(4,208)
Profit after tax
7,048,632
5,261,007
2,254,429
1,725,996
Profit/(loss) attributable to:
Owners of the Company
6,940,682
5,231,738
2,219,926
1,721,356
Non-controlling interest
107,950
29,269
34,503
4,640
7,048,632
5,261,007
2,254,429
1,725,996
Other comprehensive income/(loss)
-
1
-
-
Total comprehensive income
7,048,632
5,261,008
2,254,429
1,725,996
Total comprehensive income attributable to:
Owners of the Company
6,940,682
5,231,739
2,219,926
1,721,356
Non-controlling interest
107,950
29,269
34,503
4,640
7,048,632
5,261,008
2,254,429
1,725,996
Earnings per share (EPS)
15.56
11.73
4.98
3.86
Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of changes in equity (Un-audited)
For the period July 2025-March 2026
For the period July 2025-March 2026
Taka '000
Share capital
Share premium
Excess of issue price over face value of GDRs
Capital reserve on merger
Revaluation surplus
Unrealized gain/(loss)
Retained earnings
Equity attributable to owners of the company
Non-controlling interest
Total equity
Balance as on July 01, 2025
4,461,121
5,269,475
1,689,637
294,951
1,133,870
18,149
40,239,934
53,107,137
3,977,499
57,084,636
Total comprehensive income:
Profit/(loss) for the period
-
-
-
-
-
-
6,940,682
6,940,682
107,950
7,048,632
Other comprehensive income/(loss)
-
-
-
-
-
-
-
-
-
-
Transactions with the shareholders:
Cash dividend
-
-
-
-
-
-
-
-
(37,767)
(37,767)
Others:
Adjustment for depreciation on revalued assets
-
-
-
-
(2,951)
-
2,951
-
-
-
Adjustment for deferred tax on revalued assets
-
-
-
-
664
-
-
664
-
664
Balance as on March 31, 2026
4,461,121
5,269,475
1,689,637
294,951
1,131,583
18,149
47,183,567
60,048,483
4,047,682
64,096,165
Net asset value (NAV) per share
Tk.
134.60
Share capital
Share premium
Excess of issue price over face value of GDRs
Capital reserve on merger
Revaluation surplus
Unrealized gain/(loss)
Retained earnings
Equity attributable to owners of the company
Non-controlling interest
Total equity
Balance as on July 01, 2024
4,461,121
5,269,475
1,689,637
294,951
1,137,306
18,148
35,079,327
47,949,965
3,952,938
51,902,903
Total comprehensive income:
Profit/(loss) for the period
-
-
-
-
-
-
5,231,738
5,231,738
29,269
5,261,007
Other comprehensive income/(loss)
-
-
-
-
-
1
-
1
-
1
Transactions with the shareholders:
Cash dividend
-
-
-
-
-
-
(1,784,448)
(1,784,448)
(33,687)
(1,818,135)
Others:
Adjustment for depreciation on revalued assets
-
-
-
-
(3,325)
-
3,325
-
-
-
Adjustment for deferred tax on revalued assets
-
-
-
-
748
-
-
748
-
748
Balance as on March 31, 2025
4,461,121
5,269,475
1,689,637
294,951
1,134,729
18,149
38,529,942
51,398,004
3,948,520
55,346,524
Net asset value (NAV) per share
Tk.
115.21
For the period July 2024-March 2025
Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of cash flows (Un-audited)
For the period July 2025-March 2026
July 2025 -
March 2026
Taka '000
July 2024 -
March 2025
Cash flows from operating activities
Cash receipts from customers and others
41,636,365
36,394,207
Cash paid to suppliers and employees
(32,436,664)
(30,100,181)
Cash generated from operations
9,199,701
6,294,026
Interest paid
(531,937)
(769,431)
Interest received
174,786
18,479
Income tax paid
(1,376,492)
(1,322,242)
Net cash generated from operating activities
7,466,058
4,220,832
Cash flows from investing activities
Acquisition of property, plant and equipment
(2,664,525)
(2,220,342)
Intangible assets
(282,825)
(164,411)
Disposal of property, plant and equipment
11,353
40,123
Disposal of intangible assets
18,255
-
Dividend received
1,256
975
Short term investment
(50,000)
(700,000)
Net cash used in investing activities
(2,966,486)
(3,043,655)
Cash flows from financing activities
Net increase/(decrease) in long term borrowings
(717,564)
47,161
Net increase/(decrease) in short term borrowings
(1,051,826)
1,390,117
Dividend paid
(202,106)
(1,593,640)
Net cash from/(used in) financing activities
(1,971,496)
(156,362)
Increase/(decrease) in cash and cash equivalents
2,528,076
1,020,815
Opening cash and cash equivalents
1,700,097
854,106
Effect of exchange rate changes on cash and cash equivalents
(530)
8,179
Closing cash and cash equivalents
4,227,643
1,883,100
Net operating cash flows per share
16.74
9.46
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDQRTSESFMDEMSELM
